

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/192203 A1

(51) International Patent Classification:

A61K 31/4196 (2006.01) *A61K 31/5685* (2006.01)
A61K 31/436 (2006.01) *A61K 39/00* (2006.01)
A61K 31/4439 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4741 (2006.01) *A61P 35/04* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2022/019274

(22) International Filing Date:

08 March 2022 (08.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/158,688 09 March 2021 (09.03.2021) US
63/281,143 19 November 2021 (19.11.2021) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **BHAGWAT, Shripad Venkatraman**; c/o Eli
Lilly And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **HOLMAN, Natalie Starr**; c/o Eli
Lilly And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **SALL, Daniel Jon**; c/o Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **SHAHDA, Safi**; c/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **SMYTH, Lillian Mary**; c/o Eli Lilly And Compa-
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).
YOUNG, Suzanne Rebecca Lou; c/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **YUEN, Eunice Soek Mun**; c/o Eli Lilly And Compa-
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **CRAWFORD, Bradley W.** et al.; Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: METHODS OF TREATING CANCER USING A COMBINATION OF SERD DOSING REGIMENS



(57) Abstract: Disclosed herein are dosing regimens for the administration of a com-
pound of Formula I: (I) or pharmaceutically acceptable salt thereof to patients in need
of such treatment. The dosing regimens include adjuvant therapy.

WO 2022/192203 A1